GHRP-2

1. What is it?

GHRP-2 stands for growth hormone-releasing peptide-2. It is a short synthetic molecule of six amino acids, acting on a receptor linked to ghrelin, a hormone involved in hunger. It is not equivalent to semaglutide or tirzepatide. Sharing the word peptide does not tell us whether a substance reduces appetite, increases it or acts differently. GHRP-2's effect on eating was studied directly. [70] [72]

2. Why do people turn to it?

Interest in GHRP-2 concerns stimulating growth hormone and improving body composition or appetite. These goals need to be separated: a stronger appetite does not help everyone and can make weight loss harder. Studies of the short-term response to GHRP-2 show increased food intake, but do not prove better muscle gains. [70] [71]

GHRP-2 has been used as a tool to test the hormonal system's response and study eating behaviour. In such a test, doctors observe whether a chosen hormone rises after stimulation. This is different from long-term treatment of a deficiency. A new Japanese publication from 2026 also discusses the usefulness of the cortisol response in diagnosing adrenal insufficiency. It did not study increasing muscle mass or the effectiveness of a weight-loss programme. [73] [70]

3. How does it work?

Stimulating the ghrelin receptor can trigger more than one response. Experiments with GHRP-2 observed GH release and increased appetite. Describing it simply as increasing growth hormone is therefore incomplete: this leaves out eating behaviour and other parts of the hormone system. A study involving lean people and people with obesity found that the eating response was preserved. It does not establish how their body weight would change over months. [70] [71]

4. What do studies actually show?

In a 2005 study, seven healthy men took part in a short experiment that observed food intake during a meal. They ate more after GHRP-2. A 2006 study involved 19 adults with stable body weight and also showed stimulation of appetite and GH secretion. These experiments lasted a few hours during study visits. They allow assessment of the body's immediate response, but do not demonstrate lasting muscle gain, fat loss or improved physical performance. [70] [71]

5. What do we still not know?

In a separate five-day study of nine healthy men, the GH response gradually weakened and mean IGF-1 did not increase. This shows why an initial hormonal response cannot support promises of a sustained effect. Administration methods and follow-up periods can change results. A change in one measure, such as a bone-turnover marker, also does not establish stronger bones or fewer future fractures. [72]

6. What are the risks?

For injected or intranasal GHRP-2 preparations, the FDA describes possible immune reactions linked to peptide aggregation and impurities. Aggregation means molecules joining into larger clusters. The regulator also lists serious events reported in treated people, including pancreatitis and increased insulin requirements, while noting that causation has not been established. It would therefore be wrong either to attribute all these events to the peptide or to consider it harmless. [69]

In sport governed by WADA anti-doping rules, this substance is prohibited at all times, including outside competition. The 2026 list names it explicitly. Use during training or a break between competitions is also covered by the ban. [108]

7. Is it an approved medicine?

Yes. Pralmorelin is present in the Japanese-approved diagnostic medicine GHRP KAKEN100 Injection. Its purpose is to help diagnose growth hormone deficiency, not to treat obesity or improve sports performance. Japanese authorisation applies to a specific preparation and does not mean that any GHRP-2 product is approved in Poland. The FDA separately describes safety concerns about products compounded from this substance in the USA. [107] [69]

8. What is new in research?

A publication from 11 September 2026 analysed records of patients undergoing hormone tests. The authors investigated whether ACTH and cortisol responses help distinguish hypothalamic from pituitary disorders. The GHRP-2 test formed one part of that assessment. This is a specific update in diagnostic knowledge, not a trial of GHRP-2 treatment. It does not justify presenting the substance as a new therapy for tiredness, obesity or the effects of ageing. [73]

Where does this information come from?

References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.